Fort Sheridan Advisors LLC boosted its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 1.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,014 shares of the biopharmaceutical company’s stock after acquiring an additional 1,492 shares during the quarter. Pfizer accounts for 1.2% of Fort Sheridan Advisors LLC’s portfolio, making the stock its 16th largest position. Fort Sheridan Advisors LLC’s holdings in Pfizer were worth $4,142,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds have also recently bought and sold shares of PFE. PYA Waltman Capital LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at $31,000. Rinkey Investments acquired a new stake in shares of Pfizer in the fourth quarter valued at $32,000. Stuart Chaussee & Associates Inc. increased its stake in shares of Pfizer by 108.3% in the first quarter. Stuart Chaussee & Associates Inc. now owns 625 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 325 shares in the last quarter. Bivin & Associates Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at $37,000. Finally, Evolution Advisers Inc. increased its stake in shares of Pfizer by 309.3% in the first quarter. Evolution Advisers Inc. now owns 794 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 600 shares in the last quarter. 66.50% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of analysts have recently weighed in on the company. StockNews.com upgraded Pfizer from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, April 19th. Morgan Stanley decreased their price target on Pfizer from $52.00 to $49.00 and set an “equal weight” rating on the stock in a report on Friday, July 8th. Berenberg Bank set a $50.00 price target on Pfizer in a report on Friday, May 27th. Barclays raised their price target on Pfizer from $50.00 to $52.00 and gave the company an “equal weight” rating in a report on Monday, August 1st. Finally, SVB Leerink reduced their target price on Pfizer from $55.00 to $53.00 and set a “market perform” rating on the stock in a report on Friday, July 29th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $57.50.
Insiders Place Their Bets
Pfizer Stock Down 1.2 %
Shares of Pfizer stock opened at $49.27 on Friday. The business’s 50 day simple moving average is $51.09 and its 200 day simple moving average is $51.10. Pfizer Inc. has a 52-week low of $40.94 and a 52-week high of $61.71. The firm has a market cap of $276.45 billion, a PE ratio of 9.64, a P/E/G ratio of 0.61 and a beta of 0.67. The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.13 and a current ratio of 1.39.
Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Pfizer had a return on equity of 44.38% and a net margin of 28.92%. The business had revenue of $27.74 billion for the quarter, compared to analyst estimates of $26.20 billion. During the same quarter last year, the firm earned $1.07 EPS. Pfizer’s revenue for the quarter was up 46.8% compared to the same quarter last year. On average, analysts predict that Pfizer Inc. will post 6.54 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Wednesday, June 29th will be given a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 3.25%. The ex-dividend date is Thursday, July 28th. Pfizer’s dividend payout ratio (DPR) is 31.31%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.